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Adenylosuccinate synthetase (AS) catalyzes the first committed step in the conversion of IMP to AMP. A cDNA was isolated from a human liver 
library which encodes a protein of 455 amino acids (M, or49.925). Alignments of human, mouse, Dicryostelium discoidrum and E. co/i AS sequences 
identify a number of invariant residues which are likely to be important for structure and/or catalysis. The human AS sequence was also 19% 
ideritical to the human urea cycle enzyme, arginosuccirlate synthetase (ASS), which catalyzes achemically similar reaction, Both human liver and 
HeLa AS mRNA showed signals of 2.3 and 2.8 kb. An unmodified N-terminus is required for function of the human AS enzyme in E. c&mutants 
lacking the bacterial enzyme. The human cDNA provides a means to assess the possible role of AS abnormalities in unclassified, idiopathic ases 
of gout. 
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1. INTRODUCTION 
The genes for de novo purine nucleotide (nt) synthesis 
in bacteria have been analyzed in detail ([28] references 
therein). Only recently have molecular approaches been 
applied to characterize these genes in higher eukaryotes. 
Avian cDNAs encoding enzymes which catalyze eight 
of the ten steps leading to IMP have been isolated in our 
laboratory by functional complementation of E. colipur 
mutants f1,2,6,18]. Similar attempts to complement an 
E. co/i purA mutant were unsuccessful in isolating the 
eukaryotic cDNA for AS. 
AS catalyzes the reaction shown in Fig. 1, which is the 
first committed step in the pathway leading from IMP 
to AMP, and is subject o feedback inhibition by AMP 
[213. AS activity is present in most tissues but is highest 
in skeletal muscle, heart, and testes [5,15,17,21]. Ele- 
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vated activity has been noted in tumors [IO]. Two 
isozymes have been reported in tissues of rat, rabbit, 
and chicken [21]. A basic form, having a p1 of 8.9 and 
low K, for aspartate, has been assigned a role in an nt 
interconversion cycle and ma.y function in purine sal- 
vage [20,21]. An acidic form, with a p1 of 5.9 and a low 
K, for IMP, is thought to have a biosynthetic role. 
However, only a single AS locus has been identified in 
CHO cells [22]. Somatic cell hybridization studies have 
localized the human AS gene to the long arm of chro- 
mosome 1, between the centromere and lq12 [14]. Prior 
to the start of this work, the only AS sequence available 
was that from the cloned E. coli gene [27]. Our efforts 
to obtain the human cDNA were greatly aided by the 
availability of a mouse cDNA sequence [9], During the 
course of our work, the sequence of AS from Dicryosre- 
hum discoideutn was published [263. 
This paper reports the isolation and analysis of the 
human cDNA encoding AS. This human cDNA will 
allow examination of rhe relationship of AS to human 
disease states. The human sequence is of interest clini- 
cally. In addition, the human enzyme has a predicted 
isoelectric point of -7, as opposed to the suggested p1 
of 5 and 9 for the two rat isoforms. No information is 
available regarding the human isoforms and few muta- 
tions in AS are known in humans suggesting that the 
enzyme is important for growth and development. A
mutated murine lymphoma cell line has been identified 
with a partial defiency in AS [23,24]. These cells synthe- 
sized large amounts of iitiP which is secreted as inosine, 
thus suggesting a link between the AS deficiency and 
hyperuricemic states. A defective AS may contribute to 
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Fig. I. Reactions catalyzed by AS and ASS. 
unclassified idiopathic gout. Isolation of the human 
cDNA is the first necessary step in further exploring 
metabolic defects in AS. 
2. EXPERIMENTAL 
The template for first strand cD?UA synthesis was human lympho- 
blast RNA. First strand synthesis was carried out using AMV reverse 
transcriptasc as outlined by the manufacturer’s specifications (lnvitro- 
&en). The resultant cDNA was used as template for PCR as suggested 
by the manufacturer’s specifications (Perkin Elmer Cctus: Gene Amp 
kit). Degenerate oligonucleotide primers were designed based upon 
conserved amino acid sequences common to the E. coli [27] and mouse 
AS [!J. Two, 26 nt primers were synthesized with &oRl( and Hind111 
linkers: S-end primer, CATGAATTCCA(A/G)TGGGNNGA(T/ 
C)GA(A/G)GG; 3’-end primer, ATGAAGCTfACNACNCC(G/ 
A)TTNCC(A/GTr)AT. The first two thenno-cycles were as follows: 
94”C, 1 min; 37OC, 2 min; 72*C over 2 min; 72”C, 2 min. The subse- 
quent 40 thcrmo-cycles were 94-C, 1 min; 50°C. 2 min; 72”C, 2 min 
followed by an extension at 72°C for 20 min. The amplified, 200 nt 
fragment was then subcloned into M13mplS for squence analysis. 
A itgtl 1 human liver cDNA library [13] was probed with the labeled 
PCR product described above. Approximately 200,000 plaques were 
plated and duplicate lifts were made onto nitroceilutose filters. Hy 
bridization, washing of the filters and autoradiography was carried 
out as previously described [2]. Following plaque purification, the 
insert from the DNA was subcloned for sequencing. 
RNA was extracted from HeLa cells and human liver as described 
[7]. Human liver poly(A)’ RNA was se!ected by oligo d(T)-cellulose 
chromatography [4], RNA was fractionated by electrophoresis in a 
I .O% agarose gel containing formaldehyde and transferred to a nitro- 
cellulose filter as described 116). Hybridization with the 2.0 kb cDNA 
insert was conducted at 42OC for 18 h as previously described [Z]. 
Filters were washed at room temperature ir;0. I % SDSI0.25xSSPE for 
30 min followed by autoradiography. Subsequent washes and autora- 
diographs were conducted at 37OC, 42°C. and 65V. Functional com- 
plementation was carried out as follows. An h’coI (nt 73) to BumHI 
restriction fragment containing an AS coding sequence (Fig. 2) was 
suDclosed into the expression vector pTRC-97c 131. The resulting 
plasmid was transformed into two E. cob’ purA strains: PC0950 
(purA54, argl61, argF55, serB28. thr25. ton449), and ES4 (purA45. 
lacy1 or Z4, tonA2, tsx-1 or tsx-70, supE44, gai-6, md2). The cells 
were grown in minimal medium 161 supplemented with 0.1% acid 
hydrolyzed casein, 0.2 pglml thiamine and ampicillin (50 pdml). 
3. RESULTS AND DISCUSSION 
3.1. Isolution and sequence of the humatl cDNA encoding 
AS 
A human PCR product of approximately 200 bp was 
amplified using degenerate oligonucleotide primers 
based on conserved regions in E. coii and mouse AS 
amino acid sequences 193, Sequence analysis demon- 
strated that the PCR product was similar but not iden- 
tical to both E. cob and mouse AS. The PCR product 
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1 CGCAGAGCAC;TTCAGTTCGCTCACTCCTCGCCGGCCGCCTCTCCTTCGGGCTCTCCTCGCGTCACTGGAGCC 
73 
(1) 
151 
(27) 
229 
(53) 
307 
(79) 
385 
(105) 
463 
(131) 
541 
(157) 
619 
(183) 
697 
(209) 
775 
(235) 
853 
(261) 
931 
(287) 
1009 
(313) 
1087 
(339) 
1165 
(365) 
1243 
(391) 
1321 
(4171 
1339 
(4431 
1477 
ATGGCGTTCGCGAGACCTACCCGGCGGCATCCTCCCTGCCCAACGGCGATTGCGGCCGCCCCAGGGCCGGCCGGAGGA 
MAFARPTRRHPPCPTAIAAAPGPAGG 
AACCGGGTGACGGTGCTGCTCGGTGCGCAGTGGGGCGACGAAGGCG~~GGTGGTGGACCTGCTGGOGCAGGAC 
NRVTVVLGAQWGDEGKGKVVDLLAQD 
GCCGACATCGTGTGCCGC~OCCAGGGAGGAAATAATGCTGGC~TA~GTTGTTGTGGATTCTGTGG~T~~GA~TT 
ADIVCRCQGGNNAGHTVVVDSVEYDF 
CATCTCTTACCCACTGCC~T~~CTG~TTCATTGG~TGGTGTGGT~TT~TCTACCTGGA 
HLLPSGIINPNVTAFIGNGVVIHLPG 
TTGTTTGAAGfUGCAGAGAAA&TGTTChUAAG&UAAGGACTAGUGGCTGGGAAAAAA G CTT TT TATCTGAC 
LFEEAEKNVQKGKCLEGWEKRLIISD 
AGAGCTCATATTGTATTTGATTTTCATCAACCAGCTCATG 
RAHIVFDFHQAA DGIQEQQRQEQAGK 
AATTTGGGTACAACAGGCATTGGCCCAG~ATTCGTCCaAAGCTGCTCGGAGTGGACTCAGGATGTGCGAC 
NLGTTKKGIGPVYSSKAARSGLRMCD 
G~~AG~CA~SG~G~TG~~AC~CTCAAGGGGTTATATGG~GATT~CC~TGGTGAGAGATGGAGTT 
LQKLKGYMEKIKPMVRDGV 
TATTTTCTATATGAGGCCCTACATGGACCACCAAACAAAATCTTGGTAGAACGTGCAAATGCAGCACTATTAGATATT 
YFLYEALHGPPKKILVEGANAALLDI 
GATTTTGGGACTTACCCTTGTAACCTCTTCAAATTGTACTGTTGGAGGTGTTTGTACTGG~TGGGTATGCCACCT 
DFGTYPFVTSSNCTVGGVCTGLGMPP 
CAAAATGTTGGAGAAGTGTATGGAGTTGTG~GC~ATA~CTAGAG~GGTATTGGTGCCTTTCCTACAGAGCAA 
QNVGEVYGVVKAYTTRVGLGAFPTEQ 
GACAATGAAATTGGAG~~A~ACAAACAAGCGGTAGAGTGGC 
DNEIGELLQTRGREFGVTTGRKRRCG 
TGGTTGGACCTCGTTTTCCTCAAATATGCTCATATGATCAT 
WLDLVLLKYAHMINGFTALALTKLDI 
TTGGACATGTTTACGGAAATCAAAGTTGCTTGCTTAC 
LDMFTEIKVGVAYKLDGEIIPHTPAN 
CAAGAAGTCTTAAAT~U;TTG~GTTCAATATkACACTCTCCCAGGATGG~CACAGACATATCAAATGCAACGGGCG 
QEVLNKVEVQYKTLPGWNTDISNARA 
TTTAAAGAACTACCTG~TGCACAAAACTATG~CGA~ATTG~GATGAGCTTC~TTC~GTT~GTGGA~ 
FKELPVNAQNYVRFIEDELQIPVKWI 
GGTGTTGGTAAATCCAGAG~TCTATGATTTTG 
GVGKSRESMIQLF 
1633 
1789 
Fig. 2. The nt sequence of the human AScDNA and the derived amino acid sequence. The numbers hown correspond to nt while the numbers 
in brackets rerer to amino acid residues. 
W:.‘BS used 3s 2 ?idX to screen a hman iiver cDNA 
library and a single positive clone was identified. Fol- 
lowing plaque purification, the clone was shown to con- 
tain an insert of approximately 2.0 kh. This 2.0 kb 
6 
frament was subcloned into a phagemid for sequenc- 
ing. 
Both strands of DNA were sequenced. The single 
open reading frame encodes a protein of 455 amino 
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hAS 
mAS 
dAS 
@AS 
hAS 
mAS 
dAS 
@AS 
hAS 
lBAS 
dAS 
eAS -------MKELEDRGIPVRE 
hAS 
mAS 
dAS 
eAS 
hAS 
mAS 
dAS 
eAS 
hAS 
mAS 
dAS 
eAS 
ERPKVLAN---- QYKSIYPTLEI 
ARFKNLAH---- 
KTFTRLVE---- 
YEALHGPPKKILV 
YEALHGPPKKVLV 
NC/A-FKDGKKVLI 
LDQARQRGDFVMF 
DKLKGYMEKIKPM YFL 
KRLKGFAERIRPM YFM 
KRYQEFAEMLKPF YYL 
DDTMAVADILTSM SDL 
hAS 
mAS 
dAS 
eAS 
hAS 
mAS 
dAS 
eAS 
hAS 
mAS 
&AS 
ehS 
hhS LQIPVKWIGVGKSRESMIQ---L-----F 
mAS LQSNGSALG---SPES------------P 
dAS VGVPIVYIGVGVERKNLIERKEL-----I 
eAS TGVPIDIISTDPDRTETMI---LRDPFDA 
Fig. 3. Amino acid sequence alignment of human (hAS), mouse (mAS), Dlctyostefiuttt divcofdcutn (dAS). E. rof/ (eAS). Black boxes indicate identity 
in all three sequences. 
acids with a Iw, of 49,925 Da (Fig. 2). The predicted M, 
is in agreement with 50 kDa reported for AS from sev- 
era1 species i2 i]. ‘Tine cDNii contained a 5’ uniranslated 
region of 72 nt and a 3’ untranslated region of 425 nt, 
and it did not have a poly(A) tail. The putative initiation 
codon at nt 73 is not preceded by a stop codon, but it 
is the first ATG in the sequence. The G/C-rich sequence 
surrounding the first ATG conforms to the consensus 
eukaryotic initiation sequence [12]. The calculated p1 of 
the human enzyme is 7.0. 
Alignment of the human AS sequence with those 
from Dictyostelium discoidem [26] and E. cofi [271 dem- 
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AS AFARPTRRHPPCPTAIAAAPGPAGGNRVTVVLGAQ~GD 
ASS -1-------1---------------------------- 
ZS 
QDA VVDSVEYDFHLLPSGITNPN 
CCL -----1-------------- 
May 1992 
Z 
R$,,,I----L~~KIYF&DVSREF~EE~UP~--~:!$: :;::’ 
HYQ GKGLE WE RL ISDRAHI FD ZJQA DG 
LRMCDL 
---AKY 
AS 
ASS 
AS 
ASS 
AS 
ASS 
ES 
Fig. 4. Align 
SERFKV TLEIDIEGELQKLKGY KI P--m.--------- (228) 
ELSCYS WRMPEFYNRFKGRNDL YA QHGIPIPVTPKNP (178) 
~ffM~;~EGA~~L -------------------(237) 
ENPK 4 PPGLYTKTQDPAKAPNTPDI (222) 
GVCTGLGMPPQNVG VVKAYTTRVGIGA (307) 
TTHQTSLELFMYLR KBGVGRIDTVENR (272) 
I 
PTEQDNErb------I LQTRGREFGV 
IGMKSRG Y TPAGTI YHAHLDIEAF 
V NKVE YKTL GWN DSS ARAFKELPVNAQNYVRFIEDE (434) 
~~~,;;dELS~N~GDYE[TDAlOPIljl ----------c-II-----I- (393) 
LQ PVKWIGVGKSRE 
-- NSLRLKEYHRLQ 
lment of human AS and ASS sequences. Identical residues are shown in black. The numbers on the right represent the positions of 
the residue at the extreme right for each enzyme. 
Onstrates 47 and 41% amino acid identity, respectively 
(Fig. 3). The mouse and human sequences have an even 
higher degree of identity as would be expected (Fig. 3) 
The degree of positional identity supports the idea that 
structural properties and catalytic mechanism have 
been retained for this enzyme throughout he course of 
evolution. Three motifs at residues 38-44, 314-317 and 
360-363 correspond to the expected consensus elements 
for GTP binding. GX4GK at residues 38-44 and 
DNXzG at residues 314-317 are thought to be involved 
in phosphoryl binding. A guanine recognition motif 
(TKKD) is present between residues 360 and 363 [26]. 
Also well conserved is the lysine residue at position 172 
which was recently shown to be important for enzyme 
activity in E. co/i by site directed mutagenesis (81. 
Argininosuccinate synthetase (ASS), a urea cycle en- 
zyme, uses aspartate as an amino donor and catalyzes 
reactions imiiar to AS (Fig. i). Amino acid alignment 
of the human AS sequence demonstrated 19% identity 
with the human ASS [19]. The sequence identity be- 
tween human AS and ASS occurs throughout he entire 
8 
sequence (Fig. 4). Conserved residues are likely to have 
roles in maintaining structure as well as participating in 
substrate binding and catalysis. The fact that both en- 
zymes utilize aspartate as a substrate suggests that some 
of the invariant residues within the two enzymes are 
likely to be required for binding. 
Deficiency in ASS results in citruilinemia and a com- 
plete absence of the enzyme would be incompatible with 
life [1 I]. Several ASS mutations leading to citrullinemia 
have recently been characterized [1 11. It was of interest 
to determine if any of these mutations corresponded to 
conserved positions found in both ASS and AS (Fig. 4). 
Several point mutations occur within the ASS sequence 
which are not conserved in AS [1 I]. However, an 
R307W substitution in patient RI corresponds to the 
invariant A&?’ in AS. No detailed kinetics of ASS from 
this patient are available [1 11. We can predict, however, 
that the corresponding R340W mutation in AS would 
likely have an effect on enzyme activity similar to that 
noted for the R307W substitution in ASS. The AS/ASS 
sequence alignment also identifies additions residues 
Volume 303. number 1 FEBS LETTERS May 1992 
A 
KB- 
B 
Fig. 5. RNA analysis. (A) Northern b:ot of human Poly(A)+ RNA@ 
pg), Exposure was for 72 hat -80°C. An RNA ladder (ELR) was used 
as a size standard (kb). (B) Northern blot of HcLa RNA (20 pg total 
RNA). 
which might be important for structure and/or catalysis 
and therefore suggests possible site-directed mutations 
to address the function of these invariant residues. 
The AS cDNA hybridized to two RNAs from human 
liver and HeLa cells with approximately equal intensi- 
ties [Fig. 5A,B). At elevated ‘washing’ temperatures nci- 
ther RNA is selectively eluted from the filter.This sug- 
gests that the two RNAs encode a single AS isoform as 
opposed to encoding two distinct isoforms of AS. 
3.2. Functional comnplemetttation and conclusions 
Previous efforts to isolate AS cDNA by complemen- 
tation of an E. co11 pwA mutant with an avian expres- 
sion library were not successful. Functional comple- 
mentation of E, colipur mutants has been used to isolate 
a number of enzymes in the de novo purine nt synthetic 
pathway from higher eukaryotes [1,2,6,18]. Functional 
complementntion was attempted using the full-length 
human cDNA. The human cDNA clone was expressed 
as an in-frame, la& fusion. Complementation of purA 
was not obtained. However, when the complete coding 
sequence was inserted into the expression vector pTRC- 
97c, which produces the human enzyme with the correct 
amino terminus, complementatioi of two p:A strains 
was obtained. Plasmids were isolated from Pur+ trans- 
formants, then re-transformed into the same purA 
strains. This plasmid complemented each pur mutant 
with high efficiency. As expected, no Pur’ transfor- 
mants were noted using the pTRC-97c vector alone. 
This result demonstrates that the correct amino termi- 
nus of AS is necessary for activity. 
The cDNA encoding human AS can be used as a tool 
to investigate the potential role of the enzyme in human 
disease. A select population of previously unclassified 
idiopathic, overproducing, hyperuricemic gout patients 
would be prime candidates for such a study. Evidence 
supporting a possible deficiency of AS underlying some 
of these cases comes from the genetic model developed 
with A-100 cells [23,24]. This cell line is a mutated 
mouse T cell lymphoma cell which is 80% deficient in 
AS activity. These cells contain four-fold elevated IMP 
levels and secrete massive amounts of inosine into the 
media [23-251. Having the human cDNA encoding AS 
will now make it possible to determine if any of the 
idiopathic gout patients’ pathophysiology is associated 
with alterations in the AS gene. 
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